Export

EN
FR
ATC codes: L01BA01
EMLc
Indication
Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2B30.0
INN
Methotrexate
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection
Oral > Solid: 2.5 mg (as sodium salt)
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.